Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP20-RLBP1
- Development stage
- Unknown
- Lead developer
- InnoVec Pharmaceutical Technology
- Modality
- Gene Therapies
- Administration
- Intravitreal
01
Overview
RP20-RLBP1 (also known as PUMCH-E111) is an adeno-associated virus (AAV) gene therapy candidate being developed by InnoVec Pharmaceutical Technology in collaboration with Peking Union Medical College Hospital (PUMCH). It is designed to treat Retinitis Pigmentosa type 20 (RP20), a rare form of hereditary retinal dystrophy caused by mutations in the RLBP1 gene. The RLBP1 gene encodes the cellular retinaldehyde-binding protein (CRALBP), which is essential for the visual cycle in the retinal pigment epithelium and Müller cells. By delivering a functional copy of the RLBP1 gene, the therapy aims to restore CRALBP activity, thereby maintaining the visual cycle and preventing further vision loss. RP20-RLBP1 is currently in Phase 1 clinical development, with the first patient dosed in 2026.
- Other names
- RP20-RLBP1RP-20-RLBP1RP 20-RLBP1PUMCH-E111PUMCH-E-111PUMCH-E 111
02
Targets
RLBP1 (Retinaldehyde Binding Protein 1)
Beyond the preview
Go deeper on RP20-RLBP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP20-RLBP1.